I am an investor that uses inverse and leveraged ETF and I oppose restrictions on my right to use these investment products.
These products are adequately explained through their prospectus.
As an investor, it is my responsibility to read and understand these documents and investors should be free to choose appropriate products for the portfolio.
Limiting these products to only high net worth individuals is inherently undemocratic and results in wealth inequalities.
These products serve a role in my investment portfolio.
The regulatory role should be limited to establishing a standard format for describing the risks and structure of these products through their prospectus.
For the Public
FINRA DATA
FINRA Data provides non-commercial use of data, specifically the ability to save data views and create and manage a Bond Watchlist.
For Industry Professionals
FINPRO
Registered representatives can fulfill Continuing Education requirements, view their industry CRD record and perform other compliance tasks.
For Member Firms
FINRA GATEWAY
Firm compliance professionals can access filings and requests, run reports and submit support tickets.
For Case Participants
DR PORTAL
Arbitration and mediation case participants and FINRA neutrals can view case information and submit documents through this Dispute Resolution Portal.
Need Help? | Check System Status
Log In to other FINRA systems
Dori Marcelino Comment On Regulatory Notice 22-08
I am an investor that uses inverse and leveraged ETF and I oppose restrictions on my right to use these investment products.
These products are adequately explained through their prospectus.
As an investor, it is my responsibility to read and understand these documents and investors should be free to choose appropriate products for the portfolio.
Limiting these products to only high net worth individuals is inherently undemocratic and results in wealth inequalities.
These products serve a role in my investment portfolio.
The regulatory role should be limited to establishing a standard format for describing the risks and structure of these products through their prospectus.